• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    MaxCyte Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/18/25 4:58:53 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $MXCT alert in real time by email
    0001287098false00012870982025-06-182025-06-18

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

    ​

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    The Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event reported): June 18, 2025

    ​

    ​

    MaxCyte, Inc.

    (Exact name of registrant as specified in its charter)

    ​

    ​

    ​

    ​

    ​

    ​

    Delaware

        

    001-40674

        

    52-2210438

    (State or other jurisdiction of
    incorporation)

    ​

    (Commission File Number)

    ​

    (IRS Employer
    Identification No.)

    ​

    9713 Key West Avenue, Suite 400

    Rockville, Maryland 20850

    (Address of principal executive offices, including zip code)

    ​

    (301) 944-1700

    (Registrant’s telephone number, including area code)

    ​

    N/A

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    ​

    ​

    ​

    ​

    ​

    Title of each class

        

    Trading
    Symbol(s)

        

    Name of each exchange
    on which registered

    Common Stock, $0.01 par value

    ​

    MXCT

    ​

    The Nasdaq Stock Market LLC

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    ​

    Emerging growth company    ☒

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    At the 2025 annual meeting of stockholders of MaxCyte, Inc. (the “Company”) held on June 18, 2025 (the “Annual Meeting”), the Company’s stockholders approved an Amendment (the “Plan Amendment”) to the MaxCyte, Inc. 2022 Equity Incentive Plan, as amended (the “2022 Plan”). The Plan Amendment increases by 2,950,000 the maximum number of shares of common stock authorized to be issued under the 2022 Plan. Further information regarding the Plan Amendment was provided in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on April 28, 2025 (the “Proxy Statement”).

    The foregoing description of the Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Plan Amendment. The Plan Amendment has been incorporated into the 2022 Plan via an Amended and Restated MaxCyte, Inc. 2022 Equity Incentive Plan (the “Amended and Restated 2022 Plan”), which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    During the Annual Meeting, the Company’s stockholders considered and approved five proposals, each of which is described in more detail in the Proxy Statement. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

    Proposal 1 – Election of Class I Directors:

    ​

    ​

    Nominee

    For

    ​

    Withhold

    ​

    Broker Non-Votes

    Maher Masoud

    69,794,241

    ​

    11,013,848

    ​

    6,613,081

    Yasir Al-Wakeel

    58,901,844

    ​

    21,906,245

    ​

    6,613,081

    Rekha Hemrajani

    59,111,391

    ​

    21,696,698

    ​

    6,613,081

    Proposal 2 – Approval of the Plan Amendment:

    ​

    For

     

    Against

     

    Abstain

    ​

    Broker Non-Votes

    74,124,667

    6,481,735

    201,687

    ​

    6,613,081

    Proposal 3 – Approval of the cancellation of admission of the Company’s common stock to trading on the AIM market of the London Stock Exchange:

    Votes For

     

    Votes Against

     

    Abstentions

    82,894,212

    4,288,690

    238,268

    Proposal 4 – Ratification of the Audit Committee’s selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025:

    Votes For

     

    Votes Against

     

    Abstentions

    87,039,354

    58,701

    323,115

    Proposal 5 – Approval of the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies:

    For

     

    Against

     

    Abstain

    84,960,605

    2,145,035

    315,530

    Because all proposals passed, the proposal to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies was deemed moot.

    ​

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit
    Number

        

    Exhibit Description

    10.1

    ​

    Amended and Restated 2022 Plan

    104

    ​

    Cover Page Interactive Data (embedded within the Inline XBRL document)

    ​

    ​

    ​

    ​

    ​

    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    ​

    MaxCyte, Inc.

    ​

    ​

    Dated: June 18, 2025

    By:

    /s/ Douglas Swirsky

    ​

    ​

    Douglas Swirsky

    ​

    ​

    Chief Financial Officer

    ​

    ​

    ​

    Get the next $MXCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MXCT

    DatePrice TargetRatingAnalyst
    11/29/2023$7.00Buy
    Craig Hallum
    10/15/2021Outperform
    Cowen
    8/24/2021$36.00Outperform
    Wedbush
    8/24/2021Outperform
    William Blair
    8/24/2021$19.00Overweight
    Stephens
    8/24/2021Outperform
    Cowen & Co.
    8/24/2021$18.00Buy
    Stifel
    8/24/2021$22.00Buy
    BTIG
    More analyst ratings

    $MXCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

      ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT™ platform and proven Flow Electroporation® technology, widely recognized for its efficient and scalable transfection capabilities

      6/11/25 2:00:00 AM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

      ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2025 financial results and reiterated its 2025 guidance. First Quarter and Recent Highlights Core business revenue of $8.2 million in the first quarter of 2025, an increase of 1% over the first quarter of 2024.Strategic Platform License (SPL) Program-related revenue was $2.1 million for the first quarter of 2025, compared to $3.2 million in the first quarter of

      5/7/25 4:05:00 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

      ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2025 after the U.S. market close on Wednesday, May 7th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance.

      4/10/25 2:00:00 AM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MXCT
    Leadership Updates

    Live Leadership Updates

    See more
    • MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

      ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as President and Chief Executive Officer. This "bottom-up" review focused on optimizing new product development, manufacturing, commercial execution, and capital allocation to enhance efficiency and align resources with strategic priorities. As part of an effort to streamline operations,

      12/9/24 2:00:00 AM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte Appoints Cynthia Collins to its Board of Directors

      ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe

      10/15/24 8:05:00 AM ET
      $CERT
      $MXCT
      $PSTX
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

      ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte's commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the Company's market impact in Cell and

      10/10/24 8:05:00 AM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MXCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Masoud Maher bought $489,066 worth of shares (100,000 units at $4.89) (SEC Form 4)

      4 - MAXCYTE, INC. (0001287098) (Issuer)

      6/10/24 5:55:54 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care